FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306319915> ?p ?o ?g. }

• W4306319915 abstract "Abstract Background Empagliflozin (EMPA), Dapagliflozin (DAPA) and Ertugliflozin (ERTU) are selective sodium glucose co-transporter 2 inhibitors (SGLT2i) acting against type 2 diabetes mellitus. Purpose Due to differences in clinical trial outcomes, we aimed to 1) compare the cardioprotective effects of selective SGLT2i in terms of infarct size (IS) reduction and 2) reveal the mechanism of cardioprotection in non-diabetic mice. Methods C57BL/6 mice were randomized and orally received EMPA (10mg/kg/day), DAPA (9.0mg/kg/day), ERTU (9.7mg/kg/day) or vehicle for 7 days. IS was measured after 30' ischemia (I), and 120' reperfusion (R). EMPA, DAPA and ERTU were given at equivalent stoichiometrically doses (ESD). Body weight and fasting blood glucose (FBG) levels were determined at baseline and at the end of the treatment. On the 7th day, mice were housed in metabolic cages for 24 hours. Urine volume (UV), food and water uptake and 24h-glucose levels were determined to examine the extend of SGLT-2 inhibition by the drugs. In a second series, the ischemic myocardium was taken (10'R), shotgun proteomics were performed and several cardioprotective pathways were evaluated. In a third series, the dominant pathways were evaluated through molecular analyses and mitochondrial functionality. The causal relationships in the mechanism of protection, was established by inhibiting the concomitant cardioprotective pathways. Static, the specific STAT-3 inhibitor and wortmannin (a PI3K inhibitor) were administered and IS was measured upon 30'I/120' R. Results EMPA and DAPA but not ERTU reduced IS at this dose. Body weight and FBG levels were not affected by the treatments. EMPA, DAPA and ERTU lead to significant increase in UV and urinary glucose levels compared to the control group independently of the water and food intake. There was no significant difference in the parameters among the different SGLT-2i indicating that the chosen doses are sufficient to produce the same pharmacological SGLT-2 inhibition in mice. Proteomics revealed mitochondrial metabolism and NF-kB signaling as significant. Only EMPA preserved mitochondrial functionality in complex I & II linked oxidative phosphorylation. NF-kB, RISK and STAT-3 activation and the downstream reduction in apoptosis were evident in EMPA and DAPA groups coinciding with IS reduction. Static and wortmannin significantly attenuated IS reduction both in EMPA and DAPA groups indicating that STAT-3 and PI3K activation are the leading mechanisms of cardioprotection. Among several upstream mediators, fibroblast growth factor 2 (FGF-2) and caveolin-3 were increased in EMPA and DAPA groups. Conclusions Short term EMPA, DAPA and ERTU at the chosen ESD inhibit SGLT-2i in a similar extent but only EMPA and DAPA reduce IS. Our study reveals drug specific effects on cardioprotection against I/R injury. Cardioprotection afforded by EMPA and DAPA are STAT-3 and PI3K dependent and associated with increased FGF-2 and Cav-3 expression. Funding Acknowledgement Type of funding sources: None." @default.
• W4306319915 created "2022-10-16" @default.
• W4306319915 creator A5002762491 @default.
• W4306319915 creator A5003003528 @default.
• W4306319915 creator A5004825622 @default.
• W4306319915 creator A5014722176 @default.
• W4306319915 creator A5021188315 @default.
• W4306319915 creator A5024391183 @default.
• W4306319915 creator A5025554746 @default.
• W4306319915 creator A5042200919 @default.
• W4306319915 creator A5056988538 @default.
• W4306319915 creator A5058837759 @default.
• W4306319915 creator A5060980856 @default.
• W4306319915 creator A5067130154 @default.
• W4306319915 creator A5081254452 @default.
• W4306319915 creator A5081407170 @default.
• W4306319915 creator A5088997998 @default.
• W4306319915 date "2022-10-01" @default.
• W4306319915 modified "2023-10-18" @default.
• W4306319915 title "Cardioprotection by selective SGLT2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?" @default.
• W4306319915 doi "https://doi.org/10.1093/eurheartj/ehac544.2905" @default.
• W4306319915 hasPublicationYear "2022" @default.
• W4306319915 type Work @default.
• W4306319915 citedByCount "0" @default.
• W4306319915 crossrefType "journal-article" @default.
• W4306319915 hasAuthorship W4306319915A5002762491 @default.
• W4306319915 hasAuthorship W4306319915A5003003528 @default.
• W4306319915 hasAuthorship W4306319915A5004825622 @default.
• W4306319915 hasAuthorship W4306319915A5014722176 @default.
• W4306319915 hasAuthorship W4306319915A5021188315 @default.
• W4306319915 hasAuthorship W4306319915A5024391183 @default.
• W4306319915 hasAuthorship W4306319915A5025554746 @default.
• W4306319915 hasAuthorship W4306319915A5042200919 @default.
• W4306319915 hasAuthorship W4306319915A5056988538 @default.
• W4306319915 hasAuthorship W4306319915A5058837759 @default.
• W4306319915 hasAuthorship W4306319915A5060980856 @default.
• W4306319915 hasAuthorship W4306319915A5067130154 @default.
• W4306319915 hasAuthorship W4306319915A5081254452 @default.
• W4306319915 hasAuthorship W4306319915A5081407170 @default.
• W4306319915 hasAuthorship W4306319915A5088997998 @default.
• W4306319915 hasBestOaLocation W43063199151 @default.
• W4306319915 hasConcept C126322002 @default.
• W4306319915 hasConcept C134018914 @default.
• W4306319915 hasConcept C2775887513 @default.
• W4306319915 hasConcept C2777180221 @default.
• W4306319915 hasConcept C2777422806 @default.
• W4306319915 hasConcept C2779676291 @default.
• W4306319915 hasConcept C541997718 @default.
• W4306319915 hasConcept C555293320 @default.
• W4306319915 hasConcept C71924100 @default.
• W4306319915 hasConcept C98274493 @default.
• W4306319915 hasConceptScore W4306319915C126322002 @default.
• W4306319915 hasConceptScore W4306319915C134018914 @default.
• W4306319915 hasConceptScore W4306319915C2775887513 @default.
• W4306319915 hasConceptScore W4306319915C2777180221 @default.
• W4306319915 hasConceptScore W4306319915C2777422806 @default.
• W4306319915 hasConceptScore W4306319915C2779676291 @default.
• W4306319915 hasConceptScore W4306319915C541997718 @default.
• W4306319915 hasConceptScore W4306319915C555293320 @default.
• W4306319915 hasConceptScore W4306319915C71924100 @default.
• W4306319915 hasConceptScore W4306319915C98274493 @default.
• W4306319915 hasIssue "Supplement_2" @default.
• W4306319915 hasLocation W43063199151 @default.
• W4306319915 hasOpenAccess W4306319915 @default.
• W4306319915 hasPrimaryLocation W43063199151 @default.
• W4306319915 hasRelatedWork W2151345870 @default.
• W4306319915 hasRelatedWork W2199901734 @default.
• W4306319915 hasRelatedWork W2927285401 @default.
• W4306319915 hasRelatedWork W2948420741 @default.
• W4306319915 hasRelatedWork W3081222781 @default.
• W4306319915 hasRelatedWork W3143290529 @default.
• W4306319915 hasRelatedWork W3179513936 @default.
• W4306319915 hasRelatedWork W3209125166 @default.
• W4306319915 hasRelatedWork W4283275733 @default.
• W4306319915 hasRelatedWork W4287219193 @default.
• W4306319915 hasVolume "43" @default.
• W4306319915 isParatext "false" @default.
• W4306319915 isRetracted "false" @default.
• W4306319915 workType "article" @default.